IL261799A - Cannabionid and cannabis-based compositions and methods for the treatment of inflammatory conditions of the gastrointestinal tract - Google Patents

Cannabionid and cannabis-based compositions and methods for the treatment of inflammatory conditions of the gastrointestinal tract

Info

Publication number
IL261799A
IL261799A IL261799A IL26179918A IL261799A IL 261799 A IL261799 A IL 261799A IL 261799 A IL261799 A IL 261799A IL 26179918 A IL26179918 A IL 26179918A IL 261799 A IL261799 A IL 261799A
Authority
IL
Israel
Prior art keywords
cannabinoids
cannabis
inflammatory bowel
based compounds
therapeutic uses
Prior art date
Application number
IL261799A
Other languages
English (en)
Hebrew (he)
Original Assignee
To Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by To Pharmaceuticals Llc filed Critical To Pharmaceuticals Llc
Publication of IL261799A publication Critical patent/IL261799A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL261799A 2016-03-28 2018-09-16 Cannabionid and cannabis-based compositions and methods for the treatment of inflammatory conditions of the gastrointestinal tract IL261799A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662313882P 2016-03-28 2016-03-28
PCT/IL2017/050388 WO2017168422A1 (en) 2016-03-28 2017-03-28 Cannabionid and cannabis-based compositions and methods for the treatment of inflammatory conditions of the gastrointestinal tract

Publications (1)

Publication Number Publication Date
IL261799A true IL261799A (en) 2018-10-31

Family

ID=58579244

Family Applications (1)

Application Number Title Priority Date Filing Date
IL261799A IL261799A (en) 2016-03-28 2018-09-16 Cannabionid and cannabis-based compositions and methods for the treatment of inflammatory conditions of the gastrointestinal tract

Country Status (11)

Country Link
US (2) US20190091198A1 (cg-RX-API-DMAC10.html)
EP (1) EP3436001A1 (cg-RX-API-DMAC10.html)
JP (1) JP2019510060A (cg-RX-API-DMAC10.html)
KR (1) KR20180130544A (cg-RX-API-DMAC10.html)
AU (1) AU2017242161A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018069860A2 (cg-RX-API-DMAC10.html)
CA (1) CA3018951A1 (cg-RX-API-DMAC10.html)
IL (1) IL261799A (cg-RX-API-DMAC10.html)
MX (1) MX2018011392A (cg-RX-API-DMAC10.html)
WO (1) WO2017168422A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201807098B (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019130215A1 (en) * 2017-12-27 2019-07-04 To Pharmaceuticals Llc Cannabis compositions for the treatment of inflammatory skin disorders
MX2020007394A (es) 2018-01-10 2020-09-03 Brightseed Inc Metodo para modular el metabolismo.
WO2019159185A1 (en) * 2018-02-19 2019-08-22 To Pharmaceuticals Llc Compositions and methods for the treatment of protein energy wasting
US20210393572A1 (en) * 2018-09-28 2021-12-23 Visceral Therapeutics Inc. Pharmaceutically active cannabis-based compositions and methods of use for treating gastrointestinal conditions
US20220015397A1 (en) * 2018-12-10 2022-01-20 Natural Extraction Systems, LLC Compositions with novel cannabinoid and terpene profiles
AU2019412825A1 (en) * 2018-12-27 2021-08-12 Buzzelet Development And Technologies Ltd. Herbal preparation-enriched cannabinoid composition and method of treatment
WO2020219829A1 (en) * 2019-04-26 2020-10-29 Natural Extraction Systems, LLC Compositions comprising non-crystalline forms of cannabidiol
US10993928B2 (en) 2019-04-26 2021-05-04 Natural Extraction Systems, LLC Compositions comprising non-crystalline forms of cannabidiol
MX2022001225A (es) * 2019-07-29 2022-03-17 Brightseed Inc Metodo para mejorar la salud digestiva.
US20230190670A1 (en) * 2019-12-02 2023-06-22 Natural Extraction Systems, LLC Compositions comprising novel cannabinoid and terpene profiles
WO2021140183A1 (en) * 2020-01-08 2021-07-15 Société des Produits Nestlé S.A. Oral solid cannabinoid oil composition for treating gastrointestinal disorders
JP2023529476A (ja) * 2020-06-12 2023-07-10 ゼリラ セラピューティクス オペレーションズ ピーティーワイ リミテッド 慢性疼痛を治療するための組成物及び方法
GB202101732D0 (en) * 2021-02-08 2021-03-24 Tts Pharma Ltd A cannabinoid mixture
AU2022324615A1 (en) 2021-08-04 2024-02-15 Demeetra Agbio, Inc. Cannabinoid derivatives and their use
WO2023060323A1 (en) * 2021-10-15 2023-04-20 Bod Science Limited Terpene-containing formulations and use thereof
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2450741A (en) * 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
US20140245495A1 (en) 2013-02-25 2014-08-28 Ytzchak Cohen Cannabis plant named midnight
US20140245494A1 (en) 2013-02-25 2014-08-28 Ytzchak Cohen Cannabis plant named erez
US20140259228A1 (en) 2013-02-25 2014-09-11 Ytzchak Cohen Cannabis plant named 'avidekel'

Also Published As

Publication number Publication date
WO2017168422A1 (en) 2017-10-05
AU2017242161A1 (en) 2018-11-01
KR20180130544A (ko) 2018-12-07
ZA201807098B (en) 2020-01-29
MX2018011392A (es) 2019-07-08
EP3436001A1 (en) 2019-02-06
CA3018951A1 (en) 2017-10-05
US20190091198A1 (en) 2019-03-28
US20200397743A1 (en) 2020-12-24
BR112018069860A2 (pt) 2020-11-03
JP2019510060A (ja) 2019-04-11

Similar Documents

Publication Publication Date Title
PL3169328T3 (pl) Pochodne chinoliny do leczenia chorób zapalnych
HUE060711T2 (hu) Makrociklusos vegyületek betegségek kezelésére
IL251530B (en) Use of cannabinoids in the treatment of degenerative skeletal muscle diseases
HUE053115T2 (hu) Topikális gyógyszerészeti formulációk gyulladással összefüggõ állapotok kezelésére
HUE045043T2 (hu) Terápiás szerek neurodegeneratív betegségekre
EP3291824C0 (en) ANTIMICROBIAL THERAPY
HUE053309T2 (hu) Új sók és gyógyászati készítmények gyulladásos betegségek kezelésére
EP2948149A4 (en) BY TOXIC ALDEHYDIC DISEASES AND TREATMENT
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
MA39483A (fr) Agents thérapeutiques cibles
HUE051296T2 (hu) Benzoxazinon-származékok bõrbetegségek kezelésére
HUE054828T2 (hu) Eljárások és készítmények a bél enteroendokrin rendszerének stimulálására a vele kapcsolatos betegségek és állapotok kezelésére
SI4119569T1 (sl) Konjugirane protismiselne spojine za uporabo v terapiji
EP3538643A4 (en) GENETICALLY MODIFIED INTESTINAL TISSUE AND USES THEREOF
IL257764B (en) Methods for treatment of diseases
IL251836A0 (en) Compositions and methods for physiological delivery using cannabidiol
LT3119384T (lt) Intrahepatinių cholestazinių ligų gydymas
MA39950A (fr) Dérivé de 2-acylaminothiazole pour le traitement des maladies des voies urinaires et de la vessie
IL263372A (en) Treatment of intrahepatic cholestatic diseases
FR3017298B1 (fr) Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
HUE063820T2 (hu) Módszerek kardiovaszkuláris betegségek kezelésére
DK3182980T3 (da) Behandling af glykosyleringsmangelsygdomme
DK3096775T5 (da) SOCS-mimetika til behandling af sygdomme
PL3538132T3 (pl) Insulina doodbytnicza do leczenia nieswoistego zapalenia jelit
IL259381B (en) Mirabegron for the treatment of retinal diseases